Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;207(6):2648-2652.
doi: 10.1111/bjh.70152. Epub 2025 Sep 12.

A decade of pharmacovigilance in France: Immune checkpoints join the list of usual suspects for drug-induced immune haemolytic anaemia

Guillaume Brenac  1 , Anne Dautriche  2 , Romane Freppel  2 , Anthony Facile  3 , Bruno Revol  4 , Mathilde Beurrier  5 , Bernard Bonnotte  1 , Sylvain Audia  1
Affiliations

A decade of pharmacovigilance in France: Immune checkpoints join the list of usual suspects for drug-induced immune haemolytic anaemia

Guillaume Brenac et al. Br J Haematol. 2025 Dec.
No abstract available

Keywords: autoimmune haemolytic anaemia; drug adverse events.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to report related to the study.

Figures

FIGURE 1
FIGURE 1
Flowchart and characteristics of patients reported with drug‐induced immune haemolytic anaemia in the French pharmacovigilance database. Data are reported as median [1st–3rd quartiles] or as numbers (frequency). *Other solid tumours were breast, ear–nose–throat, kidney, pancreas, stomach or skin cancers (1 case each), +other immune‐mediated diseases were anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis, Hashimoto's disease, myasthenia gravis, neutrophilic dermatosis, optical neuromyelitis, psoriatic arthritis, rheumatoid arthritis and Takayasu arteritis (1 case each).
FIGURE 2
FIGURE 2
Description of drug‐induced immune haemolytic anaemia cases. (A) Drug classes involved in DIIHA. (B) Median time for DIIHA diagnosis after drug initiation, and median time for improvement after drug discontinuation, for the different drug classes. Histograms represent the median with ranges (bars). (C) Lowest haemoglobin levels for the different causative drug classes. Box and whisker plots showing medians with interquartile (boxes) and minimal and maximal values (bars).
See this image and copyright information in PMC

References

    1. Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24(4–5):143–150. - PubMed
    1. Mayer B, Bartolmas T, Yurek S, Salama A. Variability of findings in drug‐induced immune haemolytic anaemia: experience over 20 years in a single Centre. Transfus Med Hemother. 2015;42(5):333–339. - PMC - PubMed
    1. Zantek ND, Koepsell SA, Tharp DR Jr, Cohn CS. The direct antiglobulin test: a critical step in the evaluation of hemolysis. Am J Hematol. 2012;87(7):707–709. - PubMed
    1. Leger RM, Arndt PA, Garratty G. How we investigate drug‐induced immune hemolytic anemia. Immunohematology. 2014;30(2):85–94. - PubMed
    1. Garratty G, Arndt PA. Drugs that have been shown to cause drug‐induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology. 2014;30(2):66–79. - PubMed

LinkOut - more resources